Cigna Group is contending with elevated industry-wide medical costs that are expected to weigh on its Healthcare segment in 2025, according to CFRA, which downgraded the stock to Hold in a note ...

45+ Medicare companies and brands analyzed by our team of experts. 30+ years of combined experience covering Medicare and personal finance. Governed by NerdWallet's strict guidelines for editorial ...

Each of the six major national insurers turned a profit in the first quarter of 2025, though financial pressures related to ...

Retirees who sign up for Medicare could be in for a rude surprise: Their drug coverage may be worse than what they had with ...

Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Three years since COVID-19 abated, UnitedHealth Group, CVS Health and other insurers are still feeling the hangover, ...

The drug has been chosen as the sole ustekinumab by BCBSM, Florida Healthcare Plan, and other closed-door health systems.

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...

Clinical studies showed that Yesintek is a biosimilar to Stelara and has similar pharmacokinetic, safety, efficacy and ...

Health insurers, employers and pharmacy benefit managers may be insulated from the immediate effects of drug tariffs, but ...